Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
在共价布鲁顿酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中,Pirtobrutinib 与 Idelalisib/Rituximab 或 Bendamustine/Rituximab 的 III 期试验 (BRUIN CLL-321)
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00166
Sharman, Jeff P; Munir, Talha; Grosicki, Sebastian; Roeker, Lindsey E; Burke, John M; Chen, Christine I; Grzasko, Norbert; Follows, George; Mátrai, Zoltán; Sanna, Alessandro; Qiu, Lugui; Feng, Ru; Hua, Vu Minh; Jurczak, Wojciech; Ritgen, Matthias; Yi, Shuhua; Bosch, Francesc; Coombs, Catherine C; Bao, Katherine; Patel, Vishalkumar; Liu, Bin; Compte, Livia; Guntur, Ananya; Wang, Denise Y; Hill, Marisa; Leow, Ching Ching; Ghia, Paolo; Barr, Paul M